Medicare Spending and Potential Savings on Brand-Name Drugs With Available Generic Substitutes Excluded by 2 Large Pharmacy Benefit Managers, 2012 Through 2015

JAMA Intern Med. 2018 Apr 1;178(4):567-569. doi: 10.1001/jamainternmed.2017.8016.


This study uses Medicare Part D drug utilization and spending data to estimate potential Part D program and beneficiary savings on brand-name medications excluded by pharmacy benefit managers for which generic substitutes are available.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cost Savings / economics*
  • Drug Substitution / economics*
  • Drugs, Generic / economics*
  • Health Expenditures*
  • Humans
  • Medicare
  • Medicare Part D / economics*
  • Organizational Policy
  • United States


  • Drugs, Generic